

Curriculum Vitae

Name: Chang, Pei-Hung (張沛泓)

Sex: Male

Birth Place: Taipei, Taiwan

Citizenship: Taiwan

Affiliation: Chang Gung Memorial Hospital, Keelung

Office Address: No.200, Lane 208, Jijin 1st Road, Keelung, Taiwan

TEL: (02)24329292 ext. 2360

FAX:(02)24325273

E-mail Address: ph555chang@gmail.com

Language: Chinese, English, Taiwanese

Education:

Sep 2000-Jun 2007 Taipei Medicine University, Taiwan

June 2016- May 2017, Research fellow at Human Nutrition Center, David Geffen School of Medicine, at the University of California, Los Angeles (UCLA), USA.

Employment Record:

Aug 2007- July 2010 Resident, Department of Internal Medicine, Chang Gung Memorial Hospital, Keelung

Aug 2010- July 2012 Fellow and Chief Resident, Division of Hemato-oncology, Department of Internal Medicine, Chang Gung Memorial Hospital, Keelung

Aug 2012-Present Attending Physician, Division of Hemato-Oncology, Department of Internal Medicine, Chang-Chung Memorial Hospital, Keelung, Taiwan

July 2017-Present Assistant Professor, Division of Hemato-Oncology, Department of Internal Medicine, Chang-Chung Memorial Hospital, Keelung, Taiwan

July 2020-Present Associate Professor, Division of Hemato-Oncology, Department of Internal Medicine, Chang-Chung Memorial Hospital, Keelung, Taiwan

July 2020-Present Director, Cancer Center, Chang-Chung Memorial Hospital, Keelung, Taiwan

Aug 2023-Present Assistant Professor, Chinese Medicine, College of Medicine, Chang Gung University

Board Certification:

July, 2007 Board of Physician

December, 2010 Board of Taiwan Society of Internal Medicine

November, 2012 Board of Medical Oncology of the Chinese Oncology Society

May, 2013 Board of Taiwan Academy of Hospice Palliative Medicine

Membership of Academic Society:

Taiwan Society of Internal Medicine

Chinese Oncology Society

Taiwan Academy of Hospice Palliative Medicine

Taiwan Academy of Cancer Research

Research Interest: Nutritional oncology, Circulating tumor cells

Research Project:

1. CMRPG2D0171-3 Integrating circulating tumor cells in predicting treatment response and prognosis of metastatic/recurrent breast cancer
2. CMRPG2G0681-2 The circulating tumor cells changes in patients with head and neck cancer and its clinical significance
3. CMRPG2J0061-3 Circulating tumor cells change in patients with metastatic colorectal cancer and its clinical significance
4. XPRPG2H0041-4 Nutrition support using NutraWell powder, OmegaRich containing fish oil supplement and Selenium containing selenium yeast to improve outcomes in patients with unresectable or metastatic pancreatic cancer undergoing palliative chemotherapy
5. CMRPG2J0061 A novel study using a high purity isolation platform for circulating tumor cells MSI detection in patients with metastatic colorectal cancer
6. CMRPG2N0341 A novel study using liquid biopsy in patients with advanced pancreatic cancer
7. CORPG2P0051 Liquid biopsy in patients with esophageal cancer
8. NMRPD1P0031 A novel study using liquid biopsy in patients with gastrointestinal cancer: A technology development and clinical correlation study

A. Publications (2017-2023)

1. **Chang PH**, Wang CH, Chen YC, Yang SY, Chou WC, Hsieh CH, Kuan FC, Yeh KY. Glasgow prognostic score after concurrent chemoradiotherapy is a prognostic factor in advanced head and neck cancer. *Chin J Cancer Res* 2017; 29(3):172-178.
2. Lu CH, Liu CT, **Chang PH**, Hung CY, Li SH, Yeh TS, Hung YS, Chou WC. Develop and validation a nomogram to predict the recurrent probability in patients with major salivary gland cancer. *J Cancer*. 2017; 20;8(12):2247-2255.
3. Wang CH, Chang CJ, Yeh KY, **Chang PH**, Huang JS. The Prognostic Value of HER2-Positive Circulating Tumor Cells in Breast Cancer Patients: A Systematic Review and Meta-Analysis. *Clin Breast Cancer*. 2017; 17(5):341-349.
4. **Chang PH**, Yeh KY, Wang CH, Chen EY, Yang SW, Huang JS, Chou WC, Hsieh JC. Impact of the pretreatment Glasgow prognostic score on treatment tolerance, toxicities, and survival in patients with advanced head and neck cancer undergoing concurrent chemoradiotherapy. *Head Neck*. 2017;39(10):1990-1996
5. **Chang PH**, Yeh KY, Wang CH, Chen EY, Yang SW, Huang JS, Chou WC, Hsieh JC. Impact of metformin on patients with advanced head and neck cancer undergoing concurrent chemoradiotherapy. *Head Neck*. 2017; 39(8):1573-1577
6. **Chang PH**, Yeh KY, Li Z. Nutritional therapy for head and neck cancer. *J Nutr Oncol*. 2017;2(4): 4-13
7. Chou WC, Wu MH, **Chang PH(Co-first author)**, Hsu HC, Chang GJ, Huang WK, Wu CE,

- Hsieh JC. A Prognostic Model Based on Circulating Tumour Cells is Useful for Identifying the Poorest Survival Outcome in Patients with Metastatic Colorectal Cancer. *Int J Biol Sci*. 2018;14(2):137-146.
8. Hung YS, Chen JS, Chen YY, Lu CH, **Chang PH**, Chou WC. Incidence, Risk Factors, and Outcomes of Arterial Thromboembolism in Patients with Pancreatic Cancer Following Palliative Chemotherapy. *Cancers (Basel)*. 2018;10(11), 432.
 9. Hung CY, Lai CC, Chen PT, Lu CH, **Chang PH**, Yeh KY, Li SH, Liu KH, Hung YS, Chen JS, Lin YC, Chou WC. Impact of body mass index on long-term survival outcome in Asian populations with solid cancer who underwent curative-intent surgery: A six-year multicenter observational cohort study. *J Cancer*. 2018;9(18):3316-3325.
 10. **Chang PH**, Hsieh JC, Yeh KY, E Chen EY, Yang SW, Huang JS, Lai CH, Wu TH, Huang YM, Chang YS, Chou WC, Wang CH. Prognostic nutritional index relevance in chemoradiotherapy for advanced oral cavity, oropharyngeal and hypopharyngeal cancer. *Asia Pac J Clin Nutr*. 2018;27(5):996-1001.
 11. Pan YP, Hsu TY, Lin JY, Ho CJ, Kuan CY, Chou WC, Lai CH, **Chang PH**, Yeh KY. Prognostic Significance of Low Body Mass Index and Betel-Quid Use in the 5-Year Survival Rates of Esophageal Squamous Cell Carcinoma Patients. *Nutr Cancer* 2018; 70(8): 1315-21.
 12. Chen JS, Hung CY, Chang H, Liu CT, Chen YY, Lu CH, **Chang PH**, Hung YS, Chou WC. Venous Thromboembolism in Asian Patients with Pancreatic Cancer Following Palliative Chemotherapy: Low Incidence but a Negative Prognosticator for Those with Early Onset. *Cancers (Basel)* 2018; 10(12), 501.
 13. Chang CF, Huang PW, Chen JS, Chen YY, Lu CH, **Chang PH**, Hung YS, Chou WC. Prognostic Factors for Advanced Pancreatic Cancer Treated with Gemcitabine Plus S-1: Retrospective Analysis and Development of a Prognostic Model. *Cancers (Basel)* 2019; 11(1), 57.
 14. Wang HM, Wu MH, **Chang PH(Co-first author)**, Lin HC, Liao CD, Wu SM, Hung TM, Lin CY, Chang TC, Tzu-Tsen Y, Hsieh JC. The change in circulating tumor cells before and during concurrent chemoradiotherapy is associated with survival in patients with locally advanced head and neck cancer. *Head Neck* 2019; 41(8):2676-2687.
 15. Lai HL, Chen YY, Lu CH, Hung CY, Kuo YC, Chen JS, Hsu HC, Chen PT, **Chang PH**, Hung YS, Chou WC. Effect of S-1 on survival outcomes in 838 patients with advanced pancreatic cancer: A 7-year multicenter observational cohort study in Taiwan. *Cancer Med* 2019; 8:2085-2094
 16. Chou WC, Chen YY, Hung CY, Chen JS, Lu CH, **Chang PH**. Evolution of the chemotherapeutic landscape and survival outcome in patients with metastatic pancreatic cancer:

a four-institute cohort study in Taiwan, 2010-2016. *Cancer Manag Res* 2019; 11: 2119-27.

17. **Chang PH**, Wu MH, Liu SY, Wang HM, Huang WK, Liao CT, Yen TC, Ng SH, Chen JS, Lin YC, Lin HC, Hsieh JC. The Prognostic Roles of Pretreatment Circulating Tumor Cells, Circulating Cancer Stem-Like Cells, and Programmed Cell Death-1 Expression on Peripheral Lymphocytes in Patients with Initially Unresectable, Recurrent or Metastatic Head and Neck Cancer: An Exploratory Study of Three Biomarkers in One-time Blood Drawing. *Cancers (Basel)* 2019; 11(4), 540
18. Hang Huong Ling, Yi-Ping Pan, Chung-Wei Fan, Wen-Ko Tseng, Jen-Seng Huang, Tsung-Han Wu, Wen-Chi Chou, Cheng-Hsu Wang, Kun-Yun Yeh and ***Chang PH(Correspondence)**. Clinical Significance of Serum Glutamine Level in Patients with Colorectal Cancer. *Nutrients* 2019; 11(4), 898.
19. Huang PW, Chang CF, Hung CY, Hsueh SW, **Chang PH**, Yeh KY, Chen JS, Chen YY, Lu CH, Hung YS, Chou WC. Validation and application of a prognostic model for patients with advanced pancreatic cancer receiving palliative chemotherapy. *Cancer Med.* 2019; 8(12):5554-5563.
20. Liu KH, Hung CY, Hsueh SW, **Chang PH**, Chen YY, Lu CH, Chen PT, Yeh KY, Huang PW, Tsang NM, Hung YS, Chou WC. Lung Metastases in Patients with Stage IV Pancreatic Cancer: Prevalence, Risk Factors, and Survival Impact. *J Clin Med.* 2019; 8(9). pii: E1402.
21. Lee SH, **Chang PH**, Chen PT, Lu CH, Hung YS, Tsang NM, Hung CY, Chen JS, Hsu HC, Chen YY, Chou WC. Association of time interval between cancer diagnosis and initiation of palliative chemotherapy with overall survival in patients with unresectable pancreatic cancer. *Cancer Med.* 2019; 8(7):3471-3478.
22. Hsieh JC, Wang HM, Wu MH, Chang KP, **Chang PH**, Liao CT, Liao CT. Review of emerging biomarkers in head and neck squamous cell carcinoma in the era of immunotherapy and targeted therapy. *Head Neck.* 2019; 41 Suppl 1:19-45.
23. Yu SM, Lu CH, Liu KH, Chen PT, **Chang PH**, Hung CY, Hsueh SW, Yeh KY, Chen YY, Hung YS, Chou WC. External validation of the Besançon nomogram in Asian patients with advanced pancreatic cancer receiving second-line chemotherapy: A multi-institute experience in Taiwan. *Pancreatology.* 2020 Jan;20(1):116-124.
24. Lee CH, Hsieh JC, Wu TM, Yeh TS, Wang HM, Lin YC, Chen JS, Lee CL, Huang WK, Hung TM, Yen TT, Chan SC, Chou WC, Kuan FC, Hu CC, ***Chang PH(Correspondence)**. Baseline circulating cancer stem-like cells predict survival in patients with metastatic breast Cancer. *BMC Cancer.* 2019 Dec 2;19(1):1167.
25. Yu SM, Lu CH, Liu KH, Chen PT, **Chang PH**, Hung CY, Hsueh SW, Yeh KY, Chen YY, Hung YS, Chou WC. External validation of the Besançon nomogram in Asian patients with

advanced pancreatic cancer receiving second-line chemotherapy: A multi-institute experience in Taiwan. *Pancreatology*. 2020 (1), 116-124

26. Hu CC, Weng CH, Hua MC, **Chang PH**, Lin CL, Chen YT, Chien CH, Lin ST, Chien RN. New Scoring Method to Predict Risk of Hepatocellular Carcinoma in Patients with Chronic Hepatitis C After Pegylated Interferon and Ribavirin Therapy. *J Interferon Cytokine Res*. 2020 Feb;40(2):82-91.
27. Chou WC, **Chang PH**, Chen PT, Wang HM, Yeh KY, Lu CH, Hung YS, Tung-Chieh Chang J, Tsang NM, Ho YW, Chen SY, Lee SH, Hung CY, Wang LJ, Liao KC, Lin CH, Tang WR, Lin YC. Clinical Significance of Vulnerability Assessment in Patients with Primary Head and Neck Cancer Undergoing Definitive Concurrent Chemoradiation Therapy. *Int J Radiat Oncol Biol Phys*. 2020 Jan 25:S0360-3016(20)30057-2.
28. Ling HH, Yeh KY, Ng SH, Wang CH, Lai CH, Wu TH, **Chang PH**, Chou WC, Chen FP, Lin YC. Determining Malnutrition Assessment Criteria to Predict One-Year Mortality for Locally Advanced Head and Neck Cancer Patients Undergoing Concurrent Chemoradiotherapy. *Nutrients*. 2020 Mar 20;12(3):836. doi: 10.3390/nu12030836.
29. Kuo HC, **Chang PH**, Wang CH. Impact of Diabetes Mellitus on Head and Neck Cancer Patients Undergoing Concurrent Chemoradiotherapy. *Sci Rep*. 2020 May 7;10(1):7702. doi: 10.1038/s41598-020-64844-1.
30. Hsu CC, Liu KH, **Chang PH**, Chen PT, Hung CY, Hsueh SW, Yeh KY, Chen YY, Lu CH, Hung YS, Chou WC. Development and validation of a prognostic nomogram to predict survival in patients with advanced pancreatic cancer receiving second-line palliative chemotherapy. *Journal of gastroenterology and hepatology*. 2020; 35(10), 1694-1703.
31. Pan YP, Kuo HC, Hsu TY, Lin JY, Chou WC, Lai CH, **Chang PH**, Yeh KY. Body Mass Index-Adjusted Body Weight Loss Grading Predicts Overall Survival in Esophageal Squamous Cell Carcinoma Patients. *Nutr Cancer*. 2021;73(7):1130-1137.
32. Hung CY, Hsueh SW, Lu CH, **Chang PH**, Chen PT, Yeh KY, Wang HM, Tsang NM, Huang PW, Hung YS, Chen SC, Chou WC. A prospective nutritional assessment using Mini Nutritional Assessment-short form among patients with head and neck cancer receiving concurrent chemoradiotherapy. *Support Care Cancer*. 2021;29(3):1509-1518.
33. Kun-Yun Yeh, Hang Huong Ling, Shu-Hang Ng, Cheng-Hsu Wang, **Pei-Hung Chang**, Wen-Chi Chou, Fang-Ping Chen, Yu-Ching Lin. Role of the Appendicular Skeletal Muscle Index for Predicting the Recurrence-Free Survival of Head and Neck Cancer. *Diagnostics*. 2021; 11(2): 309.
34. Hsueh SW, Lai CC, Hung CY, Lin YC, Lu CH, Yeh KY, Tsang NM, Hung YS, **Chang PH**, Chou WC. A comparison of the MNA-SF, MUST, and NRS-2002 nutritional tools in

predicting treatment incompleteness of concurrent chemoradiotherapy in patients with head and neck cancer. *Support Care Cancer*. 2021;29(9):5455-5462.

35. Yu YL, Fan CW, Tseng WK, **Chang PH**, Kuo HC, Pan YP, Yeh KY. Correlation Between the Glasgow Prognostic Score and the Serum Cytokine Profile in Taiwanese Patients with Colorectal Cancer. *Int J Biol Markers*. 2021 Jun;36(2):40-49.
36. Huang WK, Hsu HC, Chang SH, Chou WC, **Chang PH**, Chiang SF, Chang JW, Chen JS, Yang TS, See LC. Real-World Effectiveness of Adjuvant Oxaliplatin Chemotherapy in Stage III Colon Cancer: A Controlled Interrupted Time Series Analysis. *Front Pharmacol*. 2021; 29(12):693009.
37. Yu YL, Tseng WK, Fan CW, **Chang PH**, Kuo HC, Pan YP, Yeh KY. Pretreatment Nutrition-Inflammation Biomarkers Correlated with Differential Cytokine Profiles in Taiwanese Patients with Colorectal Cancer. *Nutr Cancer*. 2021(29):1-11.
38. Lin YC, Ling HH, **Chang PH**, Pan YP, Wang CH, Chou WC, Chen FP, Yeh KY. Comorbidity, Radiation Duration, and Pretreatment Body Muscle Mass Predict Early Treatment Failure in Taiwanese Patients with Locally Advanced Oral Cavity Squamous Cell Carcinoma after Completion of Adjuvant Concurrent Chemoradiotherapy. *Diagnostics (Basel)*. 2021 Jul 2;11(7):1203.
39. Su TP, Huang JS, **Chang PH**, Lui KW, Hsieh JC, Ng SH, Chan SC. Prospective comparison of early interim 18F-FDG-PET with 18F-FLT-PET for predicting treatment response and survival in metastatic breast cancer. *BMC Cancer*. 2021; 21(1):908.
40. Lin YC, Ling HH, **Chang PH**, Pan YP, Wang CH, Chou WC, Chen FP, Yeh KY. Concurrent Chemoradiotherapy Induces Body Composition Changes in Locally Advanced Head and Neck Squamous Cell Carcinoma: Comparison between Oral Cavity and Non-Oral Cavity Cancer. *Nutrients*. 2021; 26;13(9):2969.
41. Huang YH, Hung YS, Lai CC, Ho MM, Yeh KY, Yang C, Lu CH, Tseng CK, Tsang NM, Hung CY, Hsueh SW, **Chang PH**, Ho YW, Lin YC, Chou WC. Impact of Frailty on Treatment Outcome in Patients With Locally Advanced Esophageal Cancer Undergoing Concurrent Chemoradiotherapy. *Anticancer Res*. 2021;41(10):5213-5222.
42. Su PH, Hsueh SW, Tseng CK, Ho MM, Su PJ, Hung CY, Yeh KY, **Chang PH**, Hung YS, Ho YW, Lin YC, Chou WC. Paclitaxel and Carboplatin Versus Cisplatin and 5-Fluorouracil in Concurrent Chemoradiotherapy in Patients With Esophageal Cancer. *In Vivo*. 2021; 35(6):3391-3399.
43. **Chang PH**, Wang HM, Kuo YC, Lee LY, Liao CJ, Kuo HC, Hsu CL, Liao CT, Lin HC, Huang PW, Wu MH, Hsieh CH. Circulating p16-Positive and p16-Negative Tumor Cells Serve as Independent Prognostic Indicators of Survival in Patients with Head and Neck Squamous Cell Carcinomas. *J. Pers. Med*. 2021; 11, 1156.
44. Wen-Chi Chou, Cheng-Chou Lai, Chia-Yen Hung, Shun-Wen Hsueh, Kun-Yun Yeh, Chang-Hsien Lu, Ngan-Ming Tsang, **Pei-Hung Chang**, Ya-Wen Ho, Shih-Ying Chen, Yu-Ching Lin, Yu-Shin Hung. Clinical Significance of Frailty on Treatment Outcome in

Nongeriatric Patients With Head and Neck Cancer and Esophageal Cancer Undergoing Curative-Intent Concurrent Chemoradiotherapy. *Cancer Control* 2022; 1, 1-10

45. YC Lin, CH Wang, HH Ling, YP Pan, **PH Chang**, WC Chou, FP Chen, Kun-Yun Yeh. Inflammation Status and Body Composition Predict Two-Year Mortality of Patients with Locally Advanced Head and Neck Squamous Cell Carcinoma under Provision of Recommended Energy Intake during Concurrent Chemoradiotherapy. *Biomedicines* 2022, 10(2), 388.
46. Chen HK, Su PJ, Wang YL, Chang KC, Su YL, **Chang PH**, Kuan FC, Hsieh CH, Kuo YC, Sheng TW, Chang CF, Yu SM, Huang WK, Lin YC, Tsan DL, Yu KJ, Lin PH, Chen HY, Chang YH, Pang ST, Chuang CK, Lai EC. Long Term Use and Risk of Major Adverse Cardiac Events: Comparing Enzalutamide and Abiraterone in Chemotherapy-Naïve Patients with Metastatic Castration-Resistant Prostate Cancer. 2022 Nov 8.
47. Liu YY, Lin CL, Weng CH, **Chang PH**, Chien CH, Huang KC, Hua MC, Hu CC. Older Age and High α -Fetoprotein Predict Higher Risk of Hepatocellular Carcinoma in Chronic Hepatitis-B-Related Cirrhotic Patients Receiving Long-Term Nucleos(t)ide Analogue Therapy. *Diagnostics (Basel)*. 2022 Aug 28;12(9):2085. doi: 10.3390/diagnostics12092085.
48. Huang WK, Ho WP, Hsu HC, Chang SH, Chen DY, Chou WC, **Chang PH**, Chen JS, Yang TS, See LC. Risk of cardiovascular disease among different fluoropyrimidine-based chemotherapy regimens as adjuvant treatment for resected colorectal cancer. *Front Cardiovasc Med*. 2022, 3;9:880956.
49. Wang CH, Ling HH, Liu MH, Pan YP, **Chang PH**, Lin YC, Chou WC, Peng CL, Yeh KY. Treatment-Interval Changes in Serum Levels of Albumin and Histidine Correlated with Treatment Interruption in Patients with Locally Advanced Head and Neck Squamous Cell Carcinoma Completing Chemoradiotherapy under Recommended Calorie and Protein Provision. *Cancers (Basel)*. 2022 Jun 24;14(13):3112. doi: 10.3390/cancers14133112.
50. **Chang PH**, Lee CH, Wu TM, Yeh KY, Wang HM, Huang WK, Chan SC, Chou WC, Kuan FC, Kuo HC, Kuo YC, Hu CC, Hsieh JC. Association of early changes of circulating cancer stem-like cells with survival among patients with metastatic breast cancer. *Ther Adv Med Oncol*. 2022 Jul 15;14:17588359221110182.
51. Chen HK, Su PJ, Wang YL, Chang KC, Su YL, **Chang PH**, Kuan FC, Hsieh CH, Kuo YC, Sheng TW, Chang CF, Yu SM, Huang WK, Lin YC, Tsan DL, Yu KJ, Lin PH, Chen HY, Chang YH, Pang ST, Chuang CK, Lai EC. Long-term use and risk of major adverse cardiac events: Comparing enzalutamide and abiraterone in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer. *Int J Cancer*. 2023 Mar 15;152(6):1191-1201.
52. Chang YS, **Chang PH**, Wang DH, Chen CB, Huang CF. Axitinib Rechallenge Restores the Anticancer Effect after Nivolumab: A Case Report. *Int J Mol Sci* 2023 Jul 29;24(15):12149.
53. Li H, Chiang CL, Kwak KJ, Wang X, Doddi S, Ramanathan LV, Cho SM, Hou YC, Cheng TS, Mo X, Chang YS, Chang HL, Cheng W, Tsai WN, Nguyen LTH, Pan J, Ma Y, Rima XY, Zhang J, Reategui E, Chu YS, Chang PM, **Chang PH**, Huang CF, Wang CH, Shan YS, Li CP, Fleisher M, Lee LJ. Extracellular Vesicular Analysis of Glypican 1 mRNA and Protein for

Pancreatic Cancer Diagnosis and Prognosis. *Adv Sci (Weinh)*. 2024 Jan 10:e2306373.

54. **PH Chang**, HY Chen, YS Chang, PJ Su, WK Huang, CF Lin, JCH Hsieh, CT Wu. Effect of Clinical Complete Remission Following Neoadjuvant Pembrolizumab or Chemotherapy in Bladder-Preservation Strategy in Patients with Muscle-Invasive Bladder Cancer Declining Definitive Local Therapy. *Cancers* 2024;16 (5), 894

B. Presentation

1. International Uro-Oncological Symposium: Update on the Management of Urologic Malignancies. Chang Gung Memorial Hospital, Linkou, Taiwan, December 7, 2013, Oral presentation
2. FRANC ASIA 2018, Fresenius Kabi Advanced Nutrition Course, Bangkok, Thailand, March 17-18, 2019, Oral presentation
3. 2nd FRANC Taiwan: Evolving: Evolving Trends in Clinical Nutrition, Taipei, Taiwan, July 22, 2019, Oral presentation
4. International symposium of cancer nutrition and immunotherapy. Chang Gung Memorial Hospital, Keelung, Taiwan, November 8, 2019, Oral presentation
5. 14th International Conference on Nutraceuticals: The latest nutraceutical application and prospects in integrative cancer treatment and prevention. Taipei, Taiwan, November 11, 2018, Oral presentation
6. 3rd Asia-Pacific Cholangiocarcinoma Conference, Taipei, Taiwan, March 15-16, 2019, Oral presentation
7. Cancer survivorship Symposium, Taipei, Taiwan, May 19, 2019, Oral presentation
8. 11th Asia Pacific Conference on Clinical Nutrition, Nanjing, China, September 20-22, 2019, Oral presentation
9. 14th China Nutrition Science Congress, Nanjing, China, September 20-22, 2019, Oral presentation
10. 15th International Conference on Nutraceuticals: The synergy of nutraceutical and medical treatments in the fight against cancer. Taipei, Taiwan, October 27, 2019, Oral presentation
11. 16th International Conference on Nutraceuticals: A new chapter of nutraceutical application in integrated tumor treatment and prevention. Incorporation of Nutrition Therapy as a Component of Cancer Therapy in Patients with Pancreatic cancer. Taipei, Taiwan, December 17, 2023, Oral presentation